Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
Université Paris-Sud · Institut Gustave Roussy · +19 more institutions
Indexed incrossrefpubmed
Abstract
Background
mutations occur in approximately 40% of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The PI3Kα-specific inhibitor alpelisib has shown antitumor activity in early studies.
Methods
-mutated cancer. Secondary end points included overall response and safety.
Citation impact
2,549
total citations
- FWCI
- 110.48
- Percentile
- 100%
- References
- 25
Citations per year
Authors
20Topics & keywords
Topics
Keywords
- Breast cancer
- Hormone receptor
- Hormone
- Human Epidermal Growth Factor Receptor 2
- Internal medicine
- Cancer research
- Oncology
- Receptor
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.